Led · Equity · Apr 2024

Curida Holding AS is an integrated contract development and manufacturing organization (CDMO) headquartered in Oslo, Norway, founded in 2015. It offers contract development and GMP manufacturing solutions for small-molecule pharmaceuticals and biologics, focusing on aseptic and non-aseptic liquid manufacturing and specializing in blow-fill-seal (BFS) and nasal spray technologies. For biologics, Curida provides upstream and downstream processing of monoclonal antibodies for in‑vitro diagnostics. Its customer base ranges from small to medium-sized pharmaceutical and biotech companies, serving European clients globally. The company plans to accelerate expansion and enhance facility capabilities following a new investment to grow its industry position. Recent corporate changes include Signet joining the board, Ole J. Dahlberg appointed Chairman, and Anders Larsson named CEO effective May 1, 2024.

Led · Series B · Mar 2023

Paragonix Technologies develops and manufactures FDA-cleared and CE-marked organ preservation devices, including the Paragonix SherpaPak®, LUNGguard™ Donor Lung Preservation System, and the LIVERguard™ System. Its devices use first-of-its-kind preservation methods that improve on traditional ice-and-cooler practices and integrate digital tracking and communication technologies. Paragonix complements its hardware with a comprehensive clinical support network and maintains one of the largest clinical registries of organ preservation data worldwide. The company says its products provide unprecedented physical and thermal protection during organ transport and deliver real-time tracking data via a native app. In 2022, over one in five thoracic donor organs transplanted in the U.S. were preserved and transported using a Paragonix device, and SherpaPak is the most commonly utilized device for U.S. heart preservation. The company is focused on expanding commercial reach, extending clinical service offerings, growing inventory, and advancing its transplant innovation pipeline. Paragonix Technologies is a medical device company developing the Sherpa product line for donor organ preservation and transportation. The Sherpa devices are single-use systems intended to provide safe, consistent cold ischemic storage for hearts and kidneys and to be used with current organ preservation solutions. Paragonix has exclusively licensed intellectual property from the University of Texas Health Science Center San Antonio and has established a pipeline of donor organ transport devices. The company is based in Braintree, Massachusetts and was founded in 2010. To date Paragonix has raised $3.4M in equity, debt financing and NIH grants and recently closed a $1.1M convertible debt round. Paragonix has achieved one FDA 510(k) clearance and filed two additional 510(k) submissions as it expands the Sherpa product line and aims to extend donor organ transport nationwide. Paragonix Technologies is a Cambridge, MA–based medical device company founded in 2010 by Dr. Lisa Maier and Tom DeBrooke. The company is commercializing single-use, portable organ preservation and transport devices branded as Sherpas. Its core technology was developed through licensing and collaboration with the South Texas Technology Management Office and The University of Texas Health Science Center at San Antonio. Paragonix began with a Sherpa for kidney transport and is planning to expand the product line to other organs. The company is focused on completing product development and regulatory submissions. It recently received a $710K loan from the Massachusetts Life Sciences Center to support those efforts.

Led · Series B · Feb 2018

Smart Medical Systems, led by CEO Gadi Terliuc, develops and manufactures gastro-intestinal endoscopy devices that enhance the performance and capabilities of existing endoscopy equipment. Its flagship G-EYE® is a novel add-on balloon device that works with standard endoscopes to assist visualization of the colon and is clinically evidenced to enhance polyp detection during cancer-prevention colonoscopy procedures. The company also commercializes NaviAid™, which is CE marked and FDA cleared and is commercially distributed in key global markets. G-EYE® is currently distributed in selected regions and the company intends to expand its commercialization. Smart Medical Systems leverages proprietary technology to improve existing endoscopy equipment performance. Smart Medical Systems develops and manufactures medical devices to improve diagnosis and therapy of gastrointestinal (GI) disorders, most notably colorectal cancer. Its flagship product, the G-EYE endoscope, uses balloon technology to uncover pre-cancerous polyps hidden behind natural folds of the colon. G-EYE is currently marketed in Europe in partnership with Pentax Medical. The company has additional products under development and commercialization designed to allow standard endoscopes to access and visualize portions of the GI tract currently only accessible with highly specialized equipment. Smart is headquartered in Israel and operates in the United States through SMART GI Inc. and in Greater China through its Hong Kong subsidiary, Medico HK Limited. The company raised $6.5M in funding, with part of the investment allocated to its Hong Kong subsidiary to advance its GI device platform for cancer prevention and endoscopic surgery in Greater China, including Hong Kong and Taiwan.

Led · Equity · Jan 2018

Leading Pharma, based in Airfield, NJ, operates as a vertically-integrated generic pharmaceutical company with internal R&D capabilities and a 53,000 square foot manufacturing plant dedicated to oral solid pharmaceuticals. Led by Co-Founder and CEO Ronald Gold, the company purchases, licenses, develops, manufactures and distributes products across many therapeutic areas under the Leading Pharma label. Since acquiring Excellium Pharmaceutical in 2014, it evolved from outsourcing development to having in-house R&D and manufacturing. The company sells to drugstore chains, distributors, wholesalers, mass merchandisers, government agencies and managed care accounts in the U.S. The recent financing will support R&D investments to expand its diverse pipeline of generic products. Management also intends to use proceeds to repay existing indebtedness.

Participated · Series A · Jul 2015

LEON Nanodrugs (branded as LEON) builds NANO systems, a hardware platform that uses the company’s proprietary FR-JET mixing technology to manufacture nanoparticles at GMP scale. The equipment is aimed at overcoming the production bottlenecks that currently hinder RNA medicines, cancer vaccines, cell and gene therapies, and other personalized treatments. LEON’s technology supports small-batch, rapid-turnaround workflows and allows customers to move from early development to commercial volumes without a full process redesign, reducing operational risk and time-to-market. Investor interest is growing as demand for scalable nanoparticle production rises; the company says customer demand is already “growing” and its systems are “market-ready.” Proceeds from the latest round will fund the global market launch of the NANO platform and expansion of the company’s commercial footprint. Financial details such as revenue or unit shipments were not disclosed, but management emphasized that the fundraising was significantly oversubscribed, indicating strong investor confidence. LEON positions itself at an inflection point, expecting to become a leading provider in the rapidly expanding field of nanoparticle-based therapeutics.